Print
Email
Print Edition Stories
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: RI plans launch of cord blood center
Rodney Brown on NECN: Hacking into medical devices
Zoll Medical Corp., the Chelmsford-based medical device maker, has received approval from the U.S. Food and Drug Administration (FDA) to market and sell a new model of the LifeVest wearable defibrillator.
Zoll’s (Nasdaq GS: ZOLL) stock was up more than four percent following news of the approval.
The LifeVest wearable defibrillator is worn by patients at risk for sudden cardiac arrest. Currently 2,000 patients are wearing older models of the LifeVest. Zoll officials say the device allows physicians to monitor patient’s long term risk for sudden cardiac arrest and make appropriate treatment plans. Doctors buy the devices and rent them out to patients.
In April, Zoll recalled its AED Plus Defibrillators due to malfunctioning batteries and self-test software that fails to detect defective batteries.
Zoll’s (Nasdaq GS: ZOLL) shares were trading at $19.25 in morning trading on Tuesday, up 4.3 percent from $18.45 at the previous close.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
